Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled + IV Amphotericin B vs IV Amphotericin B for Pulmonary Mucormycosis
NCT04502381Phase 2Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Jul 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amphotericin b deoxycholate in mucormycosis (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Overall Response Rate at 6 weeks and Adverse Events at 6 weeks. Started Jul 2020; status: completed.
02
Drugs
amphotericin b deoxycholate
03
Conditions
mucormycosis
Beyond the preview
Go deeper on NCT04502381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502381.